Last reviewed · How we verify

NCT04791917

Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study

Completed NA Results posted Last updated 27 July 2023
What this trial tests

NA trial testing Eccentric Biceps Flexion in Chronic Pain in 51 participants. Completed in 10 May 2022.

Timeline
28 October 2020
Primary endpoint
10 May 2022
10 May 2022

Quick facts

Lead sponsorUniversity of Florida
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment51
Start date28 October 2020
Primary completion10 May 2022
Estimated completion10 May 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Florida

Who can join

Adults 21 to 65, any sex, with Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Alcohol Demand: Breakpoint Primary · 48 hours after exercise

Changes in breakpoint of alcohol demand, assessed using the Alcohol Purchase Task. Breakpoint indicates the drink price at which participants report no alcohol consumption. Values represent difference scores derived from breakpoint values coded so that positive values indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women)-6.00± 7.62
Sham Delayed Onset Muscle Soreness Induction (Women)-2.07± 5.61
Delayed Onset Muscle Soreness Induction (Men)-1.81± 4.45
Sham Delayed Onset Muscle Soreness Induction (Men)-1.09± 8.51
Alcohol Demand: Omax Primary · 48 hours after exercise

Changes in Omax, assessed using the Alcohol Purchase Task. Omax reflects the highest total amount in dollars that a participant would spend on alcohol-containing beverages. Values represent difference scores derived from log-transformed Omax values coded so that positive values indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women)-.255± .497
Sham Delayed Onset Muscle Soreness Induction (Women)-.089± .20
Delayed Onset Muscle Soreness Induction (Men)-.03± .40
Sham Delayed Onset Muscle Soreness Induction (Men)-.168± .36
Alcohol Demand: Pmax Primary · 48 hours after exercise

Changes in Pmax, assessed using the Alcohol Purchase Task. Pmax reflects the price point at which demand for alcohol becomes elastic (i.e., declines in response to increasing price). Values represent difference scores derived from log-transformed Pmax values coded so that positive values indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women)-.19± .36
Sham Delayed Onset Muscle Soreness Induction (Women)-.080± .24
Delayed Onset Muscle Soreness Induction (Men).0054± .24
Sham Delayed Onset Muscle Soreness Induction (Men)-.11± .299
Alcohol Demand: Essential Value Primary · 48 hours after exercise

Changes in Essential Value, assessed using the Alcohol Purchase Task. Essential Value represents the reinforcing efficacy of alcohol, such that higher Essential Value indicates greater reinforcing efficacy. Values represent difference scores derived from Essential Values coded so that positive numbers indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women)-.18± .25
Sham Delayed Onset Muscle Soreness Induction (Women)-.072± .18
Delayed Onset Muscle Soreness Induction (Men)-.24± .22
Sham Delayed Onset Muscle Soreness Induction (Men)-.073± .28
Cannabis Demand: Intensity Primary · 48 hours after exercise

Changes in intensity of cannabis demand, assessed using the Marijuana Purchase Task. Intensity reflects the number of joints that would hypothetically be consumed if they were free. Values represent difference scores derived from log-transformed intensity values coded so that positive values indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women)-.019± .28
Sham Delayed Onset Muscle Soreness Induction (Women).12± .39
Delayed Onset Muscle Soreness Induction (Men)-.070± .31
Sham Delayed Onset Muscle Soreness Induction (Men)-.10± .54
Cannabis Demand: Breakpoint Primary · 48 hours after exercise

Changes in breakpoint of cannabis demand, assessed using the Marijuana Purchase Task. Breakpoint indicates the joint price at which participants report no cannabis consumption. Values represent difference scores derived from breakpoint values coded so that positive values indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women).40± 1.78
Sham Delayed Onset Muscle Soreness Induction (Women)-.14± 1.97
Delayed Onset Muscle Soreness Induction (Men)-.36± 1.88
Sham Delayed Onset Muscle Soreness Induction (Men)-.80± 1.59
Cannabis Demand: Omax Primary · 48 hours after exercise

Changes in Omax, assessed using the Marijuana Purchase Task. Omax reflects the highest total amount that a participant would spend on cannabis. Values represent difference scores derived from log-transformed Omax values coded so that positive values indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women).019± .45
Sham Delayed Onset Muscle Soreness Induction (Women)-.010± .20
Delayed Onset Muscle Soreness Induction (Men)-.001± .26
Sham Delayed Onset Muscle Soreness Induction (Men)-.10± .40
Cannabis Demand: Pmax Primary · 48 hours after exercise

Changes in Pmax, assessed using the Marijuana Purchase Task. Pmax reflects the price point at which demand for cannabis becomes elastic (i.e., declines in response to increasing price). Values represent difference scores derived from log-transformed Pmax values coded so that positive values indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women).0005± .22
Sham Delayed Onset Muscle Soreness Induction (Women)-.043± .21
Delayed Onset Muscle Soreness Induction (Men).014± .24
Sham Delayed Onset Muscle Soreness Induction (Men)-.10± .31
Cannabis Demand: Essential Value Primary · 48 hours after exercise

Changes in Essential Value, assessed using the Marijuana Purchase Task. Essential Value represents the reinforcing efficacy of cannabis, such that higher Essential Value indicates greater reinforcing efficacy. Values represent difference scores derived from Essential Values coded so that positive numbers indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women)-.061± .23
Sham Delayed Onset Muscle Soreness Induction (Women).059± .23
Delayed Onset Muscle Soreness Induction (Men)-.032± .162
Sham Delayed Onset Muscle Soreness Induction (Men).15± .27
Alcohol Demand: Intensity Primary · 48 hours after exercise

Changes in intensity of alcohol demand, assessed using the Alcohol Purchase Task. Intensity reflects the number of drinks that would hypothetically be consumed if they were free. Values represent difference scores derived from log-transformed number of drinks coded so that positive values indicate an increase in the demand index from baseline to follow-up.

GroupValue95% CI
Delayed Onset Muscle Soreness Induction (Women)-.094± .295
Sham Delayed Onset Muscle Soreness Induction (Women).047± .15
Delayed Onset Muscle Soreness Induction (Men).0958± .285
Sham Delayed Onset Muscle Soreness Induction (Men)-.07± .33

Sponsor's own description

Self-medication of pain by consuming alcohol and marijuana is common. However, the research regarding pain as a determinant for alcohol and marijuana use has relied on laboratory pain induction paradigms with limited clinical relevance. The study will assess demand for alcohol and marijuana before and after delayed onset muscle soreness (DOMS) induction in co-users. This will provide a clinically relevant, but time-limited, model for the effects of musculoskeletal pain on demand.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Pain

Currently open trials in the same condition.

Other University of Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing